Ajinomoto Co., Inc. (TYO:2802)
Japan · Delayed Price · Currency is JPY | Market Cap | 4.81T +75.1% |
| Revenue (ttm) | 1.58T +3.5% |
| Net Income | 134.68B +91.6% |
| EPS | 138.36 +98.3% |
| Shares Out | 956.83M |
| PE Ratio | 36.35 |
| Forward PE | 34.54 |
| Dividend | 50.00 (1.01%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 10,223,100 |
| Average Volume | 3,887,445 |
| Open | 4,818.00 |
| Previous Close | 4,958.00 |
| Day's Range | 4,712.00 - 5,030.00 |
| 52-Week Range | 2,966.50 - 5,090.00 |
| Beta | 0.41 |
| RSI | 62.70 |
| Earnings Date | May 7, 2026 |
About Ajinomoto Co.
Ajinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. The Seasonings and Foods segment offers sauces and seasoning products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names. This segment also provides instant noodles under the Knorr Cup Soup and YumYum names; coffee beverages under the Birdy and Blendy brands; powdered drink under the Birdy 3in1 name; MAXIM bra... [Read more]
Financial Performance
In fiscal year 2026, Ajinomoto Co.'s revenue was 1.58 trillion, an increase of 3.47% compared to the previous year's 1.53 trillion. Earnings were 134.68 billion, an increase of 91.65%.
Financial StatementsNews
Ajinomoto Co. Earnings Call Transcript: Q4 2026
Record sales and profit achieved in FY 2025, with strong growth in Healthcare, functional materials, and food segments. FY 2026 targets further record highs, while risks from the Middle East are being managed through flexible pricing and cost controls.
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to c...
Is MSG Maker Ajinomoto Sitting on an AI Goldmine? This Investor Thinks So
An activist investor has built a stake in a Japanese company it says has a lucrative monopoly on a material vital to artificial-intelligence infrastructure.
Ajinomoto Co. Transcript: Investor update
Governance and compliance frameworks were strengthened, with a revised code of conduct and new compliance committee. Executive compensation is being restructured to better align with performance and shareholder value, while portfolio and audit practices emphasize transparency and risk management.
Palliser Capital Publishes Value Enhancement Plan for Ajinomoto
LONDON--(BUSINESS WIRE)--Palliser Capital (“Palliser”), a top 25 shareholder of Ajinomoto Co., Inc. (“Ajinomoto” or the “Company”), today published a comprehensive presentation outlining the opportuni...
Ajinomoto Co. Transcript: Investor Day 2026
Sustainability is central to strategy, with a focus on agri-food system transformation, health, and nutrition. Key innovations like biostimulants and AjiPro-L target both environmental and business growth, supported by partnerships and financial schemes. Sales targets for these solutions are set to double by 2030.
Ajinomoto Co. Earnings Call Transcript: Q3 2026
Record highs in sales and profit were achieved in Q3 FY2025, driven by strong growth in Seasonings, Foods, and Functional Materials. Upward revisions were made to full-year profit forecasts, with robust performance expected to continue, supported by asset sales and margin improvements.
Ajinomoto Co. Earnings Call Transcript: Q2 2026
First half FY2025 results were flat year-over-year, with profit growth in healthcare and others offset by declines in frozen foods and umami seasonings. Management expects a strong recovery in the second half, supported by strategic actions, new technologies, and continued investment in innovation.
Ajinomoto Co. Transcript: Investor Update
Latin American operations are expanding with strong market shares, robust distribution, and new product launches in food and bio-fine chemicals. Sustainability initiatives like the Biocycle and Agipro L are central, with a focus on GHG reduction and digital transformation. Growth is supported by innovation, human capital, and adaptation to evolving consumer needs.
Ajinomoto Co. Earnings Call Transcript: Q1 2026
Organic sales grew 3% year-on-year, with business profit up 12% and profit margin at 13%. Strong gains in Functional Materials and Bio-Pharma offset challenges in Japan's frozen foods, while currency and raw material costs remain key risks.
Ajinomoto Co. Transcript: Investor update
Plans to double medical food sales by FY2030 focus on innovation, global expansion, and leveraging amino science. Cambrooke and Nualtra drive growth through strong patient and practitioner relationships, rapid product development, and high-margin segments, outpacing market growth.
Ajinomoto Co. Earnings Call Transcript: Q4 2025
Record FY2024 sales and business profit were achieved, despite one-time costs from structural reforms. FY2025 is forecasted to deliver further growth, with strong performance expected in seasonings, foods, and functional materials, and a major share buyback announced.
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its a...
L-Phenylalanine Market Insights and Forecast to 2030 Featuring Profiles (SWOT, Sales, Prices) of Key Players - Evonik, Ajinomoto, Daesang, and Wuxi Jinghai Amino Acid Co.
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "L-Phenylalanine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application" report has been added to...
L-Alanyl-L-Glutamine Market Report 2025: Includes Insights Into the Sales, Revenue, Price, Gross Margin & SWOT of Kyowa Hakko, Ajinomoto, and Evonik
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "L-Alanyl-L-Glutamine Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application" report has been add...
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an ent...
Ajinomoto Co. Transcript: Investor Day 2025
A rapid CEO transition was enabled by robust succession planning, with the new president expected to accelerate the 2030 roadmap. The board is evolving its strategic focus, enhancing executive compensation and audit practices, and addressing capital efficiency and corporate culture transformation.
Ajinomoto Co. Earnings Call Transcript: Q3 2025
Record revenue and profit were achieved for the first three quarters, driven by strong overseas and healthcare segments, while domestic food and coffee businesses faced margin pressure from rising raw material costs. Ongoing product innovation and market expansion support future growth.
Ajinomoto Co. Earnings Call Transcript: Q2 2025
Record interim sales and profit were achieved, with upward revisions to full-year forecasts, driven by strong overseas and functional materials performance. Domestic coffee and frozen foods faced margin pressure from rising costs, but strategic shifts and product innovation are underway. Shareholder returns were enhanced with a stock split and major buyback.
Ajinomoto Co. Earnings Call Transcript: Q1 2025
Record Q1 revenue and business profit were achieved, driven by strong overseas growth in seasonings, frozen foods, and functional materials. Strategic investments and price hikes are expected to support further profit recovery, with CDMO and Forge showing strong order momentum.
Ingredients Pioneer Ajinomoto Health & Nutrition Partners with Shiru, Leveraging AI to Discover and Develop Sweet Proteins for Use in Beverages and Specialty Products
BERKELEY, Calif.--(BUSINESS WIRE)--Ajinomoto Health & Nutrition Partners with Shiru, Leveraging AI to Discover and Develop Sweet Proteins for Use in Beverages and Specialty Products.
Ajinomoto Co. Earnings Call Transcript: Q4 2024
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Leveraging Advanced Manufacturing and Strict Quality Control for Superior Performance in Cellular Medicine TOKYO , March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 28...
Ajinomoto Co. Earnings Call Transcript: Q3 2024
Seviroli Foods Acquires a Portfolio of Italian Food Products from Ajinomoto Foods North America
GARDEN CITY, N.Y.--(BUSINESS WIRE)--Seviroli Foods LLC (“Seviroli”), a portfolio company of Mill Point Capital LLC (“Mill Point”) and a leading manufacturer of frozen pasta and other food products and...